Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Study Uncovers Mechanism Behind Cognitive Impairment in Chemotherapy Patients

XTALKS VITALS NEWS

Chemotherapy

Researchers at the University of Kansas have now identified the potential mechanism behind this side effect – commonly referred to as “chemo brain” – and may have even identified some new ways to treat and prevent it.

Share this!

April 18, 2017 | by Sarah Hand, M.Sc.

While chemotherapy remains one of the most common types of cancer treatment, it can have a number of serious side effects, including cognitive impairments. Researchers at the University of Kansas have now identified the potential mechanism behind this side effect – commonly referred to as “chemo brain” – and may have even identified some new ways to treat and prevent it.

“[Chemo brain is] something doctors learned about because patients were complaining,” said Dr. Michael A. Johnson, associate professor in the department of chemistry at the University of Kansas. “Symptoms include visual and verbal memory loss, so if you have a conversation with somebody, you may have difficulty recalling it. You might have attention deficit, so if you are trying to do taxes, it might be difficult to focus. It also can result in a decline in processing speed, so it may be more difficult to think on your toes. You may have trouble remembering words.”

Johnson and his colleagues found that 5-Fluorouracil – a chemotherapy agent commonly used to treat cancers, including breast, colorectal and pancreatic – can have a damaging effect on the myelin sheath that protects nerve cells in the brain. The researchers noted that this myelin damage translated to neurodegenerative symptoms in an area of the brain responsible for learning and memory, known as the hippocampus.



The researchers also found that treatment with chemotherapy was associated with elevated levels of hydrogen peroxide in the brains of mice. When these animals were treated with an experimental compound known as KU-32, the negative effects of hydrogen peroxide and the cognitive decline associated with chemotherapy treatment were mitigated.

“In our preliminary results, we found that hydrogen peroxide temporarily increases in the brains of chemotherapy-treated rats,” said Johnson, whose paper was published in the journal, Behavioural Brain Research. “Because hydrogen peroxide is a reactive oxygen species and potentially damaging, it may have an effect on cognitive function.

“Additionally, we may have a therapy that can serve as a preventative in order to treat it. We found that KU-32 prevents cognitive impairment, and our preliminary neurochemical data suggest that it may prevent increases in hydrogen peroxide production.”

The results of this study could help physicians treat the symptoms of chemo brain in the future. More preclinical data on KU-32 will need to be collected before the drug can be tested in human patients.


Keywords:  Cognitive Impairment, Chemotherapy, Cancer


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Samsung Bioepis and Takeda to Co-Develop Novel Biologic Drugs

August 22, 2017 - Biosimilars drugmaker Samsung Bioepis has joined forces with Takeda Pharmaceutical to develop biologic therapies in novel disease areas.

Featured In: Biotech News


Improving Administration of Blood Thinner Drugs through an Online Course for Nurses

August 22, 2017 - Patients’ refusal of blood thinners can influence a nurse’s decision to administer the drugs, but an online educational program could help to address this issue.

Featured In: Life Science News


Exploring the FDA’s Accelerated Approval Pathway

August 21, 2017 - Investigational new drugs that could fill an unmet medical need are sometimes granted “Accelerated Approval” by the US Food and Drug Administration (FDA) in an effort to make these medicines available to the patients who need them.

Featured In: Pharmaceutical News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.